Financial Summary


Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. (APVO)

$8.45
0.33 (+4.06%)
Buy
A-
Market Info
Financial Info
Financial Modelling
Symbol APVO
Price 8.45$
Beta 2.51
Volume Avrg. 0.66M
Market Cap 0.03B
Shares (2019) 40,838.49K
Last Div 0
Dividend Yield -
DCF Unlevered -
DCF Levered -
ROE -341.56% Strong Sell
ROA -75.73% Strong Sell
Operating Margin -131.37% Strong Sell
Debt / Equity 351.00% Strong Buy
P/E -8.91 Strong Sell
P/B 30.42 Strong Buy

Income Statement

Quarter data
Year 2019 2018 2017 2016
Earnings Per Share Diluted -5.550.33-2.39-0.99
Net Profit Margin -3.090.48-2.33-1.25
Weighted Average Shares Outstanding 21.1422.0340.8440.84
Revenue 36.4314.6623.0732.42
Weighted Average Shares Outstanding (Diluted) 20.2421.3422.5040.84
Gross Profit 12.259.6511.8512.50
Dividend per Share ----
Operating Income -126.94-53.95-51.66-42.60
Gross Margin 0.340.660.510.39
Income Tax Expense -15.34-23.30--
EBIT Margin -3.39-3.47-2.14-1.24
Net Income -112.426.97-53.69-40.45
Cost of Revenue 24.185.0111.2119.93
Earnings Before Tax Margin -3.51-3.81-2.33-1.38
EBIT -126.94-53.95-51.66-42.60
EBITDA -123.58-50.82-49.27-40.36
Profit Margin -3.090.48-2.33-1.25
Operating Expenses 68.1863.6063.5255.09
Earnings Per Share Basic -5.550.33-2.39-0.99
Earnings before Tax -127.75-55.89-53.69-44.70
Interest Expense ----

Balance Sheet Statement

Quarter data
Year 2019 2018 2017 2016
Short-term debt -3.330.8019.86
Other Assets -10.008.3515.05
Total current liabilities 19.5418.5117.6138.24
Cash and cash equivalents 9.687.0930.6412.45
Long-term debt 18.3815.7319.283.33
Cash and short-term investments 54.5280.7830.7424.94
Total debt 18.3819.0620.0723.19
Inventories 6.641.031.786.14
Deferred revenue 0.81---
Goodwill and Intangible Assets 14.536.085.254.42
Total non-current liabilities 22.3216.6919.483.33
Total non-current assets 20.4421.9218.8023.41
Total liabilities 41.2934.9737.0941.57
Total assets 91.86117.0167.4953.41
Other comprehensive income 131.27155.84157.79179.65
Short-term investments 44.8573.690.1012.49
Property, Plant & Equipment Net 5.915.845.203.95
Net Debt 8.7111.97-10.5610.74
Investments 44.8573.690.1012.49
Total shareholders equity 50.5782.0330.4111.84
Retained earnings (deficit) -80.69-73.72-127.41-167.86
Long-term investments ----
Receivables 4.282.145.227.02
Payables 11.497.3511.6713.04
Total current assets 71.4195.0848.6930.00

Cash Flow Statement

Quarter data
Year 2019 2018 2017 2016
Investing Cash Flow -47.3929.4672.804.10
Free Cash Flow -39.37-42.98-52.40-42.54
Depreciation & Amortization 3.363.132.392.23
Net cash flow / Change in cash 5.04-2.5820.59-18.14
Effect of forex changes on cash ----
Financing Cash Flow 89.309.53-0.7920.15
Dividend payments ----
Stock-based compensation 3.814.882.141.60
Investment purchases -44.88-99.63-16.54-
Acquisitions and disposals ----
Capital Expenditure 2.511.400.980.15
Operating Cash Flow -36.86-41.57-51.42-42.38

Retained Earning Schedule

Year 2016 2017 2018 2019
Retained Earnings (Previous Year) --81-74-127
Net Income -1127-54-40
Stock Dividends 32---
Dividend Paid ----
Retained Earnings -81-74-127-168

PPE Schedule

Year 2016 2017 2018 2019
Gross PPE -665
Annual Depreciation 3-1-2-1
Capital Expenditure 3110
Net PPE 6654

Intangible and Goodwill Schedule

Year 2016 2017 2018 2019
Intangible and Goodwill (Previous Year) -1565
New Purchases -45-100-17-
Intangible and Goodwill 15654

About


Mr. Marvin L. White
Healthcare
Biotechnology
Nasdaq Global Select

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo